Dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists deserve an honorable mention due to their astonishing results in the management of hyperglycemia and obesity, as recently shown [108,109,110,111]. The gene discussed is GCG; the disease is Hyperglycemia.